Phico Therapeutics,听a听biotechnology company developing a new generation of antibiotics to overcome antibacterial resistance,听has听appointed a new chairman.听
The appointment of Richard Nagle follows the company鈥檚 recent funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance its antibacterial therapy.听
A total of 拢13.2 million funding could be made available 鈥� in addition to the 拢7m of funding led by the British Growth Fund 鈥� should the project progress successfully to Phase 1 clinical trials.听
Nagle is an experienced听BioTech听executive and has built and developed business solutions across the international biopharma sector.听听
His focus on accelerating product development has led to successful company exits or IPO, including recent CEO听director of Immune Regulation (now Revolo Biotherapeutics), an innovative platform focused on regulating the immune system.听听
Previously,听Nagle听served as Non-Executive Director of听Peptinnovate听and as CEO of听a number of听successful drug delivery, biotechnology and medical device businesses.听听
He听takes over from听Dr.听Anthony Martin,听who has been Phico鈥檚 Chair since 2010.听
Dr.听Heather Fairhead, Phico听founder and CEO,听commented: 鈥淲e are delighted to welcome Richard as Chair of our Board with his wealth of executive and commercial experience.听听
鈥淭his will be invaluable in our next exciting phase as we exemplify听SASPject听technology in first-in-human intravenous studies and advance the science of antibacterial therapy.听听
鈥淚 would like to thank our previous chair Dr Anthony Martin for his support and dedication over the last 11 years 鈥� his guidance has been instrumental in achieving our success.鈥�听
Nagle added: 鈥淭his is an extremely exciting time for Phico Therapeutics, and I am delighted to be joining this dynamic business, which has been at the forefront of building technological solutions to antibacterial resistance.听听
鈥淚 intend to expand our presence both in the UK and Internationally.听It is clear that Phico听has built a world class team to execute on its clinical development goals and I look forward to working with听Dr.听Heather Fairhead and the management team in helping them to realise a number of great milestones for the company.鈥�听
听